YOLFTbeta
39

Aprilbio Co. Ltd.

397030 · KQ · Healthcare / Biotechnology

12,110.00KRW-40.00 (-0.33%)

Price History

Full chart

Market Stats

Previous Close12,150.00
Open12,260.00
Day Range12,070.00 – 13,310.00
52-Week Range16,450.00 – 76,700.00
Volume166.25K
Market Cap398.50B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.63
50-Day Avg21,256.40
200-Day Avg45,416.35

About

AprilBio Co.,Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOSang-Hoon Cha
  • Employees0
  • HeadquartersRoom 602, Building B, Chuncheon-si, South Korea, 24341, Korea
  • Websitehttps://www.aprilbio.com

Leadership

  • Jin-Taek KimCFO, Head of Business Management Division & Director of Administration Division
  • Sang-Hoon ChaChief Executive Officer
  • Moo Yong SongCTO & Head of Research & Planning Division and Member of BD Advisory Board
  • Seung Goo KangCSO
  • Jae Heung LeeCDO and Director of R&D Division

Financials

Income Statement

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue150.00M-23.40B200.00M027.51B2.17B
Growth (%)----99.15%-100.00%--92.11%
Gross Profit150.00M-23.40B200.00M-27.51B2.17B
Gross Margin100.00%-100.00%100.00%-100.00%100.00%
Operating Expense--18.95B11.66B-10.77B9.44B
Operating Income--9.19B4.45B-11.46B-13.39B16.75B-7.26B
Operating Margin--19.00%-5732.07%-60.86%-334.44%
EBITDA----8.34B-12.52B22.13B-8.42B
EBITDA Margin----4168.03%-80.44%-387.64%
Net Income--10.22B-52.71B-8.96B-14.13B20.01B-9.73B
Net Income Margin---225.31%-4479.64%-72.71%-447.88%
R&D-6.78B13.89B6.92B8.04B3.20B4.02B
R&D as % of Total Revenue--59.38%3462.40%-11.65%185.16%
Interest Expense-1.28B2.11B29.77M930.54M1.42B618.94M
Interest Expense % of Total Revenue--9.04%14.89%-5.16%28.50%

Balance Sheet

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-19.41B61.38B71.06B79.70B99.60B97.12B
Total Liabilities-33.19B4.21B1.90B21.95B8.61B803.77M
Total Equity--13.78B57.17B69.16B57.75B90.99B96.32B
Cash-10.13B24.38B7.28B6.59B3.35B7.07B

Cash Flow

Currency: KRW2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.33B3.25B-6.70B-10.06B21.96B-3.34B
Investing Cash Flow---31.64B-7.05B-22.80B-
Financing Cash Flow--20.33B16.31B-2.51B-
Capital Expenditure479.82M705.82M89.59M511.97M445.29M287.84M
Free Cash Flow-7.81B2.55B-6.79B-10.57B21.51B-3.63B
FCF to OCF106.55%78.29%101.34%105.09%97.97%108.61%

Earnings

Report DateSep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------21.0019.00--------
EPS Actual-166.11-99.39-118.54-123.42-73.54-270.58-94.00856.00-142.46293.1926.43-175.70-219.46-98.268.62-84.83
Surprise-------547.62%4405.26%--------
Timing----------------

Key Statistics & Ratios

Market Cap398.50B
Enterprise Value342.54B
Trailing P/E0.00
Forward P/E0.00
Price / Sales549.39
Price / Book4.38
Revenue (TTM)725.35M
Gross Profit (TTM)700.23M
EBITDA-8.95B
Profit Margin0.00%
Operating Margin-1324.10%
Return on Equity-9.65%
Return on Assets-6.14%
Shares Outstanding23.41M
Shares Float17.88M
Beta1.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 31, 20232:1